Clinical Trial Update: CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of CC-5013 (lenalidomide) in patients with cancer that did not respond to prior therapy; the study included lymphoma and small int…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Small Intestine Cancer

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Lymphoma, Small Intestine Cancer | Phase 1 | Status: COMPLETED